%0 Journal Article
%A Jecmenica Lukic, Milica
%A Kurz, Carolin
%A Respondek, Gesine
%A Grau-Rivera, Oriol
%A Compta, Yaroslau
%A Gelpi, Ellen
%A Troakes, Claire
%A Barcelona Brain Bank collaborative group, the MDS-endorsed PSP study group
%A van Swieten, John C
%A Giese, Armin
%A Roeber, Sigrun
%A Arzberger, Thomas
%A Höglinger, Günter
%A Grau-Rivera, O.
%A Compta, Y.
%A Tolosa, E.
%A Martí, M. J.
%A Valldeoriola, F.
%A Pagonabarraga, J.
%A Calopa, M.
%A Bayès, A.
%A Hernandez, I.
%A Aguilar, M.
%A Genis, D.
%A Fernandez, M.
%A Munoz-Garcia, C.
%A Antonell, A.
%A Gelpi, E.
%T Copathology in Progressive Supranuclear Palsy: Does It Matter?
%J Movement disorders
%V 35
%N 6
%@ 1531-8257
%C New York, NY
%I Wiley
%M DZNE-2020-01336
%P 984 - 993
%D 2020
%X The influence of concomitant brain pathologies on the progression rate in PSP is unclear.To analyze the frequency and severity of copathologies and their impact on the progression in PSP.We analyzed clinic-pathological features of 101 PSP patients. Diagnoses and stages of copathologies were established according to standardized criteria, including Alzheimer's disease-related pathology, argyrophilic grains, Lewy-related pathology, transactive response DNA-binding protein 43 pathology, fused in sarcoma pathology, cerebral amyloid angiopathy, and small vessel disease. Demographic data and major clinical milestones (frequency and latency to onset) were extracted from patients' files.Only 8
%K Alzheimer Disease: epidemiology
%K Brain: metabolism
%K Humans
%K Movement Disorders
%K Supranuclear Palsy, Progressive: epidemiology
%K tau Proteins: metabolism
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:32125724
%R 10.1002/mds.28011
%U https://pub.dzne.de/record/153339